ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 107,55
0,19%
Dow Jones
39 671,04
-0,51%
DAX
18 730,27
0,26%
Brent Oil
81,555
0,03%
Bitcoin
69 473,57
0,54%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Gracell Biotechnologies Inc (GRCL)

  7. Gracell Biotechnologies Inc (GRCL) Actualités

GRCL

Gracell Biotechnologies (GRCL)

Gracell Biotechnologies Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:GRCL
DateHeureSourceTitreSymboleSociété
04/03/202418h22Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:GRCLGracell Biotechnologies Inc
28/02/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GRCLGracell Biotechnologies Inc
26/02/202423h28Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:GRCLGracell Biotechnologies Inc
26/02/202423h28Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:GRCLGracell Biotechnologies Inc
22/02/202414h50Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
22/02/202414h45GlobeNewswire Inc.Gracell Biotechnologies Acquisition CompletedNASDAQ:GRCLGracell Biotechnologies Inc
20/02/202413h45GlobeNewswire Inc.Gracell Biotechnologies Announces Shareholders’ Approval of Merger AgreementNASDAQ:GRCLGracell Biotechnologies Inc
14/02/202414h20Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GRCLGracell Biotechnologies Inc
29/01/202413h00GlobeNewswire Inc.Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple MyelomaNASDAQ:GRCLGracell Biotechnologies Inc
08/01/202416h06PR Newswire (US)Kuehn Law Encourages KRTX, DSKE, RYZB, and GRCL Investors to Contact Law FirmNASDAQ:GRCLGracell Biotechnologies Inc
26/12/202312h44Dow Jones NewsGracell ADSs Take Flight Premarket on $1.2 Billion Takeover by AstraZenecaNASDAQ:GRCLGracell Biotechnologies Inc
26/12/202309h05Dow Jones NewsAstraZeneca to Buy Gracell Biotechnologies for $1.2 BillionNASDAQ:GRCLGracell Biotechnologies Inc
26/12/202308h01Business WireAstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseasesNASDAQ:GRCLGracell Biotechnologies Inc
26/12/202308h00GlobeNewswire Inc.Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseasesNASDAQ:GRCLGracell Biotechnologies Inc
21/12/202313h00GlobeNewswire Inc.Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus ErythematosusNASDAQ:GRCLGracell Biotechnologies Inc
12/12/202301h30GlobeNewswire Inc.Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023NASDAQ:GRCLGracell Biotechnologies Inc
29/11/202312h18IH Market NewsAmazon Unveils Innovative Services, Okta Discloses Data Breach, Textron Plans 2% Global Workforce Reduction, and MoreNASDAQ:GRCLGracell Biotechnologies Inc
28/11/202320h59Dow Jones NewsCabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T DrugsNASDAQ:GRCLGracell Biotechnologies Inc
27/11/202314h00GlobeNewswire Inc.Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus ErythematosusNASDAQ:GRCLGracell Biotechnologies Inc
21/11/202312h25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GRCLGracell Biotechnologies Inc
16/11/202314h00GlobeNewswire Inc.Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease SummitNASDAQ:GRCLGracell Biotechnologies Inc
13/11/202313h30GlobeNewswire Inc.Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate UpdateNASDAQ:GRCLGracell Biotechnologies Inc
08/11/202314h30GlobeNewswire Inc.Gracell Biotechnologies Wins Overall Immunology Solution of the Year by BioTech Breakthrough Awards ProgramNASDAQ:GRCLGracell Biotechnologies Inc
02/11/202314h00GlobeNewswire Inc.Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65ᵗʰ American Society of Hematology Annual Meeting & ExpositionNASDAQ:GRCLGracell Biotechnologies Inc
01/11/202321h00GlobeNewswire Inc.Gracell Biotechnologies to Participate in Four Upcoming Investor ConferencesNASDAQ:GRCLGracell Biotechnologies Inc
31/10/202314h00GlobeNewswire Inc.Gracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART™ Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingNASDAQ:GRCLGracell Biotechnologies Inc
30/10/202313h30GlobeNewswire Inc.Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023NASDAQ:GRCLGracell Biotechnologies Inc
27/09/202314h30GlobeNewswire Inc.Gracell Biotechnologies Reports Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response RateNASDAQ:GRCLGracell Biotechnologies Inc
26/09/202322h00GlobeNewswire Inc.Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple MyelomaNASDAQ:GRCLGracell Biotechnologies Inc
19/09/202315h21GlobeNewswire Inc.Gracell Biotechnologies’ CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science LeadersNASDAQ:GRCLGracell Biotechnologies Inc
 Showing the most relevant articles for your search:NASDAQ:GRCL

Dernières Valeurs Consultées

NASDAQ
WITS
Witness
BITMOT
989243
Bund Green Bond Tf 1,8% ...
BOV
VALEH10
VALEH10 Ex:91,33
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés